Heidi Mocikova

Prague, PR, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Treatment outcomes of Hodgkin lymphoma in the Czech Republic.

Treatment outcomes of Hodgkin lymphoma in the Czech Republic.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: May 22, 2026

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)

Published: March 18, 2026

Avascular Necrosis of the Femoral Head after Hodgkin Lymphoma Treatment: Analysis of Risk Factors and Mid-Term Outcomes after Total Hip Replacement

Avascular Necrosis of the Femoral Head after Hodgkin Lymphoma Treatment: Analysis of Risk Factors and Mid-Term Outcomes after Total Hip Replacement

Journal: Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca

Published: March 08, 2026

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.

Journal: Blood advances

Published: February 04, 2026

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Journal: Blood

Published: January 29, 2026

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Journal: Blood

Published: January 29, 2026

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 02, 2025

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Journal: Hematological oncology

Published: November 28, 2025

Soluble cytokines enhance risk prediction across all stages of classical Hodgkin lymphoma.

Soluble cytokines enhance risk prediction across all stages of classical Hodgkin lymphoma.

Journal: Biomarker research

Published: October 17, 2025

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Journal: Annals of hematology

Published: August 10, 2025

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Journal: Blood cancer journal

Published: July 15, 2025

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.

Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results.

Journal: Hematological oncology

Published: July 08, 2025

Showing 1-12 of 71

Last Updated: 09/26/2026